BriaCell Announces Proposed Investment by Leading Biotech Funds

Biotech Investing

BriaCell Therapeutics (TSXV:BCT) an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that it expects to enter into a securities purchase agreement of convertible notes with a leading group of Institutional and Family Office funds focused on investments in the  biotech sector for an investment of US$800,000. As quoted in the …

BriaCell Therapeutics (TSXV:BCT) an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that it expects to enter into a securities purchase agreement of convertible notes with a leading group of Institutional and Family Office funds focused on investments in the  biotech sector for an investment of US$800,000.

As quoted in the press release:

Concurrent with the Note Offering, the Company also announced today that it intends complete a non-brokered private placement (the “Non-Brokered Unit Offering”) of units of the Company (the “Units”) at a price of $0.10 per Unit for aggregate gross proceeds of up to C$4,000,000. The Non-Brokered Unit Offering is in addition to BriaCell’s proposed strategic US$800,000 Note Offering and also includes an investment from a recognized Biotech Family office in the United States. Under the Non-Brokered Unit Offering, each Unit shall consist of one Common Share and one Warrant. The Warrants will be valid for 36 months following the date of closing of the Non-Brokered Unit Offering and each Warrant will be exercisable for one Common Share at an exercise price of C$0.14.

Click here to read the full press release.

The Conversation (0)
Ă—